Delivery Order SPE2DB24D6038-SPE2DB25FEMLD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations, with a ceiling value of $2,015.92. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for Ozempic (0.25-0.5 mg/dose) pens in 3ml quantities, valued at $5,043.18. This is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, representing a non-competitive set-aside award. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3 mL formulations, with a ceiling value of $4,018.44. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $5,586.10. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation, reflecting open competition among eligible...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,153.24. This competitively awarded, firm fixed-price contract represents a single delivery order with an ultimate completion date of August 22, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) valued at $19,796.30. This competitive, non-set-aside delivery order carries a firm fixed price structure with an ultimate completion date of August 27, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $6,844.29. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without a set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,949.57 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed price contract type. The order is set to be completed by May 13, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania location. This delivery order is a non-set-aside award made through open competition, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pen 3ml pharmaceutical products, with a ceiling value of $1,566.65. This is a firm fixed price delivery order with an ultimate completion date of April 24, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB24D6038Indefinite Delivery Contract
- SPE2DB24D6038-SPE2DB25FEMLDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a contract ceiling value of $1,253.32. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 2, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The Ozempic delivery supports the Defense Health Agency and other government healthcare systems requiring diabetes medications as part of the DLA's ongoing Medical Supply Chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 5/30/25 |